Search results for " Control"

showing 10 items of 7691 documents

SYMPATHETIC NERVOUS SYSTEM AND BLOOD-PRESSURE CONTROL IN ESSENTIAL HYPERTENSION

1978

Abstract In normotensive subjects an inverse correlation was observed between an index of sympathetic nervous activity (the plasma-noradrenaline concentration during physical exercise) and reactivity to exogenous noradrenaline. This relationship was invariably disturbed in age-matched patients with essential hypertension. Multiple-regression analysis revealed a highly significant correlation between the combination of both factors and the height of mean arterial blood-pressure ( r =0·91). The findings suggest that sympathetic nervous activity and pressor response to noradrenaline together form an important determinant of the arterial blood-pressure level. An inverse relationship could be de…

AdultMaleBlood pressure controlmedicine.medical_specialtySympathetic nervous systemSympathetic Nervous SystemRestPhysical ExertionBlood PressurePhysical exerciseEssential hypertensionNorepinephrineInternal medicineReninHumansMedicineInverse correlationbusiness.industryAngiotensin IIGeneral MedicineMiddle Agedmedicine.diseaseAngiotensin IIHormonesmedicine.anatomical_structureEndocrinologyPressor responsePathophysiology of hypertensionHypertensionRegression AnalysisFemalebusinessThe Lancet
researchProduct

Herpes Simplex I virus impairs regenerative outcomes of periodontal regenerative therapy in intrabony defects: a pilot study.

2011

Aim To evaluate the impact of herpesvirus type-1 and -2 on the clinical outcomes of periodontal regenerative procedures in isolated deep intrabony pockets, in an experimental population with no detectable periodontal pathogens. Materials and Methods Seventeen periodontal intraosseous defects in 17 moderate-to-advanced periodontitis patients were treated with regenerative therapy and amelogenins. Microbiological evaluation was performed at baseline (after the completion of initial therapy) and at 1 year to exclude the presence of periodontal pathogens. Herpesviruses-1 and -2 DNA were quantified in the pocket tissues associated to the intrabony defect using molecular assays. Clinical attachme…

AdultMaleBone RegenerationCONTROLLED CLINICAL-TRIALHerpesvirus 2 HumanHEALING RESPONSEPopulationAlveolar Bone LossDentistryHerpesvirus 1 HumanACCESS FLAPStatistics NonparametricYoung AdultDental Enamel ProteinsEnamel matrix derivativemedicineAggressive periodontitisHumansPeriodontal PocketGingival RecessionYoung adulteducationBone regenerationGingival recessionGUIDED TISSUE REGENERATIONBONY DEFECTSPeriodontitiseducation.field_of_studybusiness.industryAGGRESSIVE PERIODONTITISMiddle Agedmedicine.diseaseMICROBIOTAHUMAN HERPESVIRUSESPREVALENCEGUIDED TISSUE REGENERATION MINIMALLY INVASIVE SURGICAL TECHNIQUE CONTROLLED CLINICAL-TRIAL AGGRESSIVE PERIODONTITIS HUMAN HERPESVIRUSES HEALING RESPONSE BONY DEFECTS ACCESS FLAP PREVALENCE MICROBIOTAReal-time polymerase chain reactionTreatment OutcomeChronic PeriodontitisDNA ViralGuided Tissue Regeneration PeriodontalPeriodonticsFemaleMINIMALLY INVASIVE SURGICAL TECHNIQUEmedicine.symptombusinessJournal of clinical periodontology
researchProduct

Prospective assessment of post-extraction gingival closure with bone substitute and calcium sulphate

2009

Introduction: The closure of post extraction gingival defects has not been studied in depth, although their achievement is of great importance in certain situations, such as prior to radiotherapy treatment in patients with oral cancer. The aim of this study is to assess the influence of bone substitutes on the time of closure of post extraction gingival defects. Materials and Methods: 22 patients underwent two symmetrical dental extractions. Using a split mouth model, with random assignment to one or other group, one was considered a control group (no filling with any type of material post extraction), whereas the other was considered the experimental group (filling with bone substitute and…

AdultMaleBone substituteAdolescentTooth extractionGingivaDentistrychemistry.chemical_elementCalciumCalcium Sulfatelaw.inventionYoung AdultRandomized controlled triallawMedicineHumansProspective StudiesSplit-mouth study modelClosure (psychology)Prospective cohort studyGeneral DentistryWound HealingBone substitutesbusiness.industryRandom assignmentGingival closureExtraction (chemistry)Middle Aged:CIENCIAS MÉDICAS [UNESCO]OtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASBone SubstitutesTooth ExtractionSurgeryFemaleImplantGlassbusiness
researchProduct

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

2012

SummaryBackgroundStudies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.MethodsEuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β2-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a sm…

AdultMaleBudesonidePulmonary and Respiratory MedicineSymbicort SMARTmedicine.medical_specialtyPeak Expiratory Flow RatePropensity-matched controlsDrug Administration Schedulelaw.inventionACQ-5Budesonide/formoterol maintenance and reliever therapyPharmacotherapyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsDosingBudesonideAsthmaSmokersDose-Response Relationship Drugbusiness.industrySmokingmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionDrug Therapy CombinationFemaleFormoterol FumarateFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

Ondasetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting. Results of a prospective randomized trial

1994

Background. A single‐institution, prospective, randomized open trial was performed to compare ondansetron and granisetron in the prevention of chemotherapyrelated nausea and vomiting. The effect of antemetic drugs was analyzed indipendently for patients treated with highly emetogenic chemotherapy (Study 1), and those treated with moderately emetogenic regimens (Study 2). Methods. In Study 1. 182 patients treated with chemotherapeutic regimens containing high dose cisplatin (more than 70 mg/m2) were randomized to receive 24 mg of ondasentron intravenously (i. v.) or 3 mg of granisetron i. v. for the control of acute emesis. Patients treated with fractionated chemotherapy and those followed‐u…

AdultMaleCancer ResearchNauseaVomitingmedicine.medical_treatmentAntineoplastic AgentsGranisetronchemotherapyDrug Administration Schedulelaw.inventionOndansetronRandomized controlled triallawmedicineHumansgranisetronProspective StudiesProspective cohort studyAgedChemotherapybusiness.industryMiddle AgednauseamovitingOncologyondansetronAnesthesiaAcute DiseaseVomitingFemalemedicine.symptomCisplatinbusinessmedicine.drugChemotherapy-induced nausea and vomiting
researchProduct

Randomized Multicenter Phase II Trial of Two Different Schedules of Irinotecan Combined with Capecitabine as First-Line Treatment in Metastatic Color…

2004

BACKGROUND The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC). METHODS A total of 140 patients received capecitabine at a dose of 1250 mg/m2 twice daily on Days 2–15 and irinotecan at a dose of either 300 mg/m2 on Day 1 (Arm A) or 150 mg/m2 on Days 1 and 8 (Arm B) every 3 weeks. During the course of the study, enrollment was continued using lower doses of capecitabine (1000 mg/m2 twice daily) and irinotecan (Arm A: 240 mg/m2; Arm B: 120 mg/m2) to improve the safety profile of the combinations. RESULTS Efficacy was evaluable in 134 patients (68 in…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerPhases of clinical researchCOLON CANCERIrinotecanGastroenterologyDeoxycytidineDrug Administration Schedulecolorectal carcinoma first-line treatment irinotecan and capecitabine combination Phase II triallaw.inventionCapecitabineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAdverse effectCapecitabineAgedXELIRIbusiness.industryCarcinomaCancerMiddle Agedmedicine.diseaseSurgeryIrinotecanOncologyDrug EvaluationCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drug
researchProduct

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Del…

2005

Purpose We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer. Patients and Methods A total of 360 chemotherapy-naive patients were randomly assigned to receive, every 2 weeks, either arm A (FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2 [LV5FU2]) or arm B (FOLFOX4: oxaliplatin 85 mg/m2 on day 1 with LV5FU2 regi…

AdultMaleCancer Researchmedicine.medical_specialtyRandomizationOrganoplatinum CompoundsColorectal cancerfolinic acidatropineplatinum complexLeucovorinGastroenterologylaw.inventionRandomized controlled trialFolfox protocollawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intravenousirinotecanantineoplastic agentAgedbusiness.industryoxaliplatinMiddle Agedmedicine.diseaseSurvival AnalysisOxaliplatinSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracildrug derivativeDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilIFL protocolColorectal Neoplasmsbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin…

1998

We carried out an open, randomized, phase III, multicenter clinical trial to compare, in neo-adjuvant setting, the clinical response and toxicity of the combination chemotherapy cisplatin + 5-FU with the same combination plus s.c. recombinant interleukin-2 (rIL-2) in patients with advanced (stage III IV) head and neck squamous-cell carcinoma (HNSCC). Regimen A was the classical Al Sarraf treatment: 100 mg/m2 cisplatin i.v. on day 1 plus 1000 mg m(-2) day(-1) 5-FU on days 1-5 as a continuous infusion. Regimen B was the same as regimen A plus 4.5 MIU/day rIL-2 s.c. on days 8-12 and 15-19. Treatment was repeated every 3 weeks for three cycles. A total of 33 patients were enrolled in the study;…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmunologyAntineoplastic AgentsGastroenterologyGroup Blaw.inventionRandomized controlled triallawInternal medicinemedicineHumansImmunology and AllergyAgedChemotherapybusiness.industryCombination chemotherapyMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryRegimenOncologyEpidermoid carcinomaHead and Neck NeoplasmsFluorouracilCarcinoma Squamous CellInterleukin-2Drug Therapy CombinationFemaleFluorouracilCisplatinbusinessProgressive diseasemedicine.drugCancer Immunology, Immunotherapy
researchProduct

Anatomical Correlate of Impaired Covert Visual Attentional Processes in Patients with Cerebellar Lesions

2010

In the past years, claims of cognitive and attentional function of the cerebellum have first been raised but were later refuted. One reason for this controversy might be that attentional deficits only occur when specific cerebellar structures are affected. To further elucidate this matter and to determine which cerebellar regions might be involved in deficits of covert visual attention, we used new brain imaging tools of lesion mapping that allow a direct comparison with control patients. A total of 26 patients with unilateral right-sided cerebellar infarcts were tested on a covert visual attention task. Eight (31%) patients showed markedly slowed responses, especially in trials in which an…

AdultMaleCerebellumgenetic structuresCerebellar lesionsNeuroimagingCerebellumReaction TimemedicineHumansVisual attentionAttentionIn patientAgedAged 80 and overGeneral NeuroscienceCognitionArticlesMiddle Agedmedicine.anatomical_structureOculomotor controlCovertVisual PerceptionFemalePsychologyNeurosciencePhotic StimulationPsychomotor PerformanceCognitive psychologyThe Journal of Neuroscience
researchProduct

Associations between adverse childhood experiences and adversities later in life. Survey data from a high-risk Norwegian sample

2019

Abstract Background A history of childhood abuse and neglect (CAN) is associated with exposure to later negative life events. CAN at an early age, multiple cooccurring exposures (cumulative events), and a high severity and frequency of exposure have potential detrimental long-term effects. Objective The present study examines the relationship between the severity of CAN and the prevalence of school difficulties and hardship at school, adult adversity and mental health. Participants and Settings: Participants were recruited from in- and outpatient mental health or substance abuse treatment facilities, child protective services (CPS), and prisons (N = 809, age range = 13–66, mean age = 27.62,…

AdultMaleChild abuse050103 clinical psychologyAdolescentmedia_common.quotation_subjectPoison controlSuicide preventionOccupational safety and healthNeglectAdverse Childhood ExperiencesRisk FactorsSurveys and QuestionnairesInjury preventionPrevalenceDevelopmental and Educational PsychologyHumansMedicineVDP::Medisinske Fag: 7000501 psychology and cognitive sciencesChild AbuseChildmedia_commonLearning DisabilitiesNorwaybusiness.industry05 social sciencesMental healthbarnemishandlingPsychiatry and Mental healthMental HealthRelative riskPediatrics Perinatology and Child HealthFemale:Social science: 200::Social work: 360 [VDP]business050104 developmental & child psychologyClinical psychology
researchProduct